Clinical Trial Update: A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of oblimersen with cisplatin and fluorouracil in gastric and esophageal cancers; the trial was terminated with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagus
• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Cancer
• Stomach Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• Oblimersen (oblimersen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-06-29